Rupa Narayan
Overview
Explore the profile of Rupa Narayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amrein P, Preffer F, Fell G, Attar E, Narayan R, Blonquist T, et al.
Leuk Lymphoma
. 2025 Mar;
:1-11.
PMID: 40070233
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical...
2.
Zhao M, Ryall S, Brody S, Harris A, Cabral K, Brownstein C, et al.
Blood Adv
. 2025 Feb;
9(5):1003-1012.
PMID: 40014425
The detection of structural variants (SVs) represents a critical component in the diagnostic evaluation and treatment of many hematologic malignancies. Although clinical SV testing mainly consists of traditional cytogenetic methodologies,...
3.
Narayan R, Alfonso Pierola A, Donnellan W, Yordi A, Abdul-Hay M, Platzbecker U, et al.
Clin Transl Sci
. 2024 Mar;
17(3):e13742.
PMID: 38494922
Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ-67571244, was assessed to identify the maximum...
4.
Brunner A, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al.
Am J Hematol
. 2023 Nov;
99(2):E32-E36.
PMID: 37994196
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised...
5.
Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, et al.
Transplant Cell Ther
. 2023 Mar;
29(7):452.e1-452.e11.
PMID: 36997024
Mutation-bearing peptide ligands from mutated nucleophosmin-1 (NPM1) protein have been empirically found to be presented by HLA class I in acute myeloid leukemia (AML). We hypothesized that HLA genotype may...
6.
Fathi A, Kim H, Soiffer R, Levis M, Li S, Kim A, et al.
Blood Adv
. 2022 Sep;
6(22):5857-5865.
PMID: 36150050
IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The IDH2 inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We...
7.
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein P, et al.
EJHaem
. 2022 Jul;
3(2):434-442.
PMID: 35846042
We conducted a single-center, open-label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory...
8.
Nardi V, McAfee S, Dal Cin P, Tsai H, Amrein P, Hobbs G, et al.
Oncologist
. 2022 May;
27(2):82-86.
PMID: 35641210
BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling molecules...
9.
Lo Y, Narayan R, Nardi V, Lennerz J
Oncologist
. 2021 Aug;
26(12):997-999.
PMID: 34407276
Precision oncology emphasizes genotyping as one of the mainstays of oncological decision-making. The core information element exchanged between the laboratory and the oncologist is the precise mutation. Specifically, it is...
10.
Ott A, Venkataraman V, Badran Y, Goldman R, Spasic S, Vyas D, et al.
Clin Case Rep
. 2021 May;
9(5):e04115.
PMID: 34026155
Arsenic trioxide (ATO) is generally well tolerated for treatment of APL. We present a patient with severe watery diarrhea and pancreatitis thought to be due to ATO toxicity in the...